DDrare: Database of Drug Development for Rare Diseases

Searched query = "Hypoplastic left heart syndrome", "HLHS"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = Allo-hMSCs; Ambrisentan; Autologous (self) mononuclear cells derived from umbilical cord blood; Autologous Human Placental Cord Blood Mononuclear Cells; Autologous Umbilical Cord Blood; Autologous cell-based delivery; Bosentan; C-kit+ cells; Curosurf; Erythropoetin; Longeveron Mesenchymal Stem Cells; METHYLPREDNISOLONE SODIUM SUCCINATE; MPC; Maternal Hyperoxygenation; Maternal hyperoxygenation; Methylprednisolone; Metyyliprednisoloninatriumsuksinaatti; Nitrogen; Normal saline; Oxandrolone; Procedure: Stage II Surgical repair; Rexlemestrocel-L; Sham; Sildenafil; Solu-Medrol; Solu-medrol; Tracleer; Vitamin C

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00513240 (ClinicalTrials.gov)	September 2006	7/8/2007	Erythropoetin Neuroprotection for Neonatal Cardiac Surgery	Erythropoetin Neuroprotection for Neonatal Cardiac Surgery	Congenital Heart Disease;Hypoplastic Left Heart Syndrome;Transposition of the Great Arteries;Aortic Arch Hypoplasia or Interruption	Drug: Erythropoetin;Drug: Normal saline	Baylor College of Medicine	The Dana Foundation;Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Completed	N/A	30 Days	All	62	Phase 1;Phase 2	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00513240
(ClinicalTrials.gov)

September 2006

7/8/2007

Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

Congenital Heart Disease;Hypoplastic Left Heart Syndrome;Transposition of the Great Arteries;Aortic Arch Hypoplasia or Interruption

Drug: Erythropoetin;Drug: Normal saline

Baylor College of Medicine

The Dana Foundation;Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Completed

N/A

30 Days

All

Phase 1;Phase 2

United States